… for the treatment of DTC, where it is recommended that almost all patients with FCDC more
than 1 cm in diameter will receive radioactive iodine-131 for postoperative RRA [14–16]. It is …

… In the present report, we describe the clinical course of patients with papillary thyroid
cancer in whom disease recurred after initial therapy with surgery and radioactive iodine (MI) …

… radioactive iodine (I-131) therapy in young patients with papillary thyroid carcinoma (PTC). …
Although radioactive iodine (I-131) therapy is generally accepted in the management of …

… radioactive iodine (RAI) in all patients with well-differentiated thyroid cancer (WDTC) greater
than 1 cm in greatest dimension and go on to recommend the routine use of RAI in patients …

… of patients, I believe the design of and adherence to an algorithmic approach to the follow-up
management of patients with DTC … For such patients, the usual management would be total …

… papillary thyroid cancer at a tertiary referral center, patients who received radioactive iodine
after … and recurrence-free survival compared with patients who underwent reoperation alone. …

… of adjuvant radioactive iodine dose on recurrence rate in high-risk papillary thyroid cancer.
… higher rate of recurrence than patients in the high-dose radioactive iodine group: 24 out of 66 …

… Papillary thyroid cancer (PTC) is a common endocrine malignancy with relatively good
prognosis. Radioactive iodine (RAI) is considered effective for patients … , radioactive iodine (RAI) …

… radioactive iodine therapy (RAI) for intermediate-risk patients… , with or without adjuvant
radioactive iodine therapy (RAI) (3). … RAI therapy for high-risk patients and select intermediate-risk …

… effect of radioactive iodine (RAI) therapy in patients treated for papillary thyroid cancer (PTC)
is chronic sialadenitis. Neck ultrasonography (US) easily recognizes radioiodine-induced …